IKBKE
MOLECULAR TARGETinhibitor of nuclear factor kappa B kinase subunit epsilon
IKBKE (inhibitor of nuclear factor kappa B kinase subunit epsilon) is targeted by 34 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting IKBKE
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | foretinib | 4.34 | 76 |
| 3 | tozasertib | 4.33 | 75 |
| 4 | ruxolitinib | 4.23 | 68 |
| 5 | bosutinib | 4.08 | 58 |
| 6 | midostaurin | 3.85 | 46 |
| 7 | nintedanib | 3.61 | 36 |
| 8 | tae 684 | 3.43 | 30 |
| 9 | fedratinib | 3.40 | 29 |
| 10 | gilteritinib | 3.40 | 29 |
| 11 | dovitinib | 3.09 | 21 |
| 12 | jnj 7706621 | 3.09 | 21 |
| 13 | at 9283 | 3.09 | 21 |
| 14 | lestaurtinib | 3.04 | 20 |
| 15 | pacritinib | 3.04 | 20 |
| 16 | adavosertib | 3.04 | 20 |
| 17 | pf 03758309 | 3.00 | 19 |
| 18 | momelotinib | 2.89 | 17 |
| 19 | orantinib | 2.89 | 17 |
| 20 | r 406 | 2.83 | 16 |
| 21 | k 252a | 2.83 | 16 |
| 22 | milciclib | 2.77 | 15 |
| 23 | pha 665752 | 2.71 | 14 |
| 24 | kw 2449 | 2.64 | 13 |
| 25 | bx 795 | 2.40 | 10 |
| 26 | su 014813 | 2.20 | 8 |
| 27 | gsk 1070916 | 2.20 | 8 |
| 28 | cyc 116 | 2.08 | 7 |
| 29 | fostamatinib | 2.08 | 7 |
| 30 | pf 03814735 | 1.79 | 5 |
| 31 | ucn 01 | 1.79 | 5 |
| 32 | gsk 625137a | 1.79 | 5 |
| 33 | amlexanox | 1.39 | 3 |
| 34 | Crizotinib | 1.10 | 2 |
About IKBKE as a Drug Target
IKBKE (inhibitor of nuclear factor kappa B kinase subunit epsilon) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 34 compounds with documented IKBKE interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
IKBKE inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.